S&P 500
7,757.17
+44.60
+0.58%
Dow
52,856.09
+360.19
+0.69%
Nasdaq
26,702.86
+278.04
+1.05%
NYSE Composite
24,253.12
+62.52
+0.26%
Russell 2000
2,781.02
+7.60
+0.27%
VIX
18.35
+1.67
+10.01%
CSTL · Castle Biosciences, Inc.
NASDAQ NMS - GLOBAL MARKET - Real Time Price • USD
Castle Biosciences Inc (CSTL)
NASDAQ NMS - GLOBAL MARKET
Health Care
$34.39
+1.24
(+3.76%)
● At close: October 21 at 4:00:00 PM EDT
DAY'S RANGE
$34.39
$33.31
$34.70
52-WEEK RANGE
$34.39
$17.72
$44.28
What's happening
- CSTL is up 3.76% today, trading at $34.39. — Live quote
- Volume today (14,844) is well below its 3-month average of 389,640. (Finnhub fundamentals)
- Reports earnings on 2026-11-05, 14 days away. (Finnhub earnings calendar)
- Last quarter's EPS beat estimates: $-0.07 actual vs. $-0.41 estimated (+83.1%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Strong buy 7
Buy 7
Hold 1
Sell 0
Strong sell 0
Aggregate ratings for 2026-10-01 (15 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
YTD RETURN
CSTL
-11.65%
vs S&P 500
-25.01%
1-YEAR RETURN
CSTL
+46.88%
vs S&P 500
+31.72%
6-MONTH RETURN
CSTL
+37.21%
3-MONTH RETURN
CSTL
+38.53%
Earnings Trends (Quarterly EPS Actual vs Estimate)
2026-07-26 (Q2 2026)
$-0.07
Est. $-0.41
BEAT +83.1%
2026-04-26 (Q1 2026)
$-0.49
Est. $-0.50
BEAT +2.0%
2026-01-26 (Q4 2025)
$-0.08
Est. $-0.29
BEAT +72.6%
2025-10-26 (Q3 2025)
$-0.02
Est. $-0.53
BEAT +96.2%
Valuation Measures & Ratios
Enterprise Value4$999.6M
Forward P/E5—
PEG Ratio6-0.62
Price / Sales (TTM1)2.94
Price / Book71.54
EV4 / Revenue2.80
EV4 / EBITDA242.57
Profit Margin-5.43%
Operating Margin-8.99%
Return on Equity (ROE8)-4.15%
Return on Assets (ROA9)-3.45%
Avg Volume (3M)389,640
Quarterly history (5 periods)
| Measure | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 |
|---|---|---|---|---|---|
| Market cap | $702.2M | $727.6M | $570.9M | $616.3M | $575.3M |
| P/E | -55.90 | -20.02 | -29.19 | -60.81 | -33.46 |
| Price/Sales | 1.97 | 2.13 | 1.66 | 1.78 | 1.72 |
| Price/Book | 1.49 | 1.58 | 1.22 | 1.35 | 1.31 |
| EV/Revenue | 1.82 | 1.98 | 1.44 | 1.57 | 1.48 |
| EV/EBITDA | -37.57 | -40.92 | 74.71 | — | — |
| ROE | -2.67% | -7.88% | -4.19% | -2.23% | -3.90% |
| ROA | -2.24% | -6.64% | -3.48% | -1.86% | -3.43% |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E/PEG unavailable (no free data source).
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Shares Short1,999,726
Change from Prior Settlement+5.28%
% of Float—
Days to Cover (Short Ratio)4.77
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Events
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
Loading chart…
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
No reviewed peer group is available for this symbol.
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Revenue growth is 20.1% on the provider's reported measure. Finnhub fundamentals ↗
- Trailing 52-week price return is +46.9%. Finnhub market metrics ↗
Potential concerns
- Net profit margin is -5.4%. Finnhub fundamentals ↗
- Latest SEC filing is Form 4, filed 2026-10-21; review it for current changes and risks. SEC EDGAR ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on CSTL
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $103.5M | $83.7M | $83.0M | $86.2M | $88.0M | $85.8M | $87.0M | $73.0M |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$3.1M | -$18.4M | -$6.8M | -$4.3M | -$27.9M | $5.1M | $5.0M | -$5.5M |
| Net income | -$2.1M | -$14.5M | -$501.0K | $4.5M | -$25.8M | $2.3M | $8.9M | -$2.5M |
| EPS (diluted) | $-0.07 | $-0.49 | $-0.02 | $0.15 | $-0.90 | $0.08 | $0.31 | $-0.09 |
| EPS (basic) | $-0.07 | $-0.49 | $-0.02 | $0.16 | $-0.90 | $0.08 | $0.32 | $-0.09 |
| Operating margin | -$3 | -$22 | -$8 | -$5 | -$32 | $6 | $6 | -$7 |
| Net margin | -$2 | -$17 | -$1 | $5 | -$29 | $3 | $10 | -$3 |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $561.2M | $547.8M | $578.6M | $562.8M | $544.7M | $501.7M | $531.2M | $514.6M |
| Total liabilities | $91.1M | $86.4M | $107.7M | $95.7M | $89.4M | $61.4M | $75.4M | $73.5M |
| Stockholders' equity | $470.0M | $461.4M | $470.9M | $467.0M | $455.4M | $440.3M | $455.8M | $441.1M |
| Total current assets | $341.1M | $328.9M | $361.1M | $357.6M | $348.7M | $349.4M | $360.2M | $344.8M |
| Total current liabilities | $56.5M | $48.8M | $68.7M | $55.3M | $50.9M | $37.3M | $49.4M | $44.3M |
| Cash & equivalents | $62.1M | $63.8M | $116.7M | $85.6M | $82.2M | $89.7M | $119.7M | $95.0M |
| Marketable securities (current) | $204.7M | $197.9M | $182.8M | $202.0M | $193.7M | $185.5M | $173.4M | — |
| Accounts receivable | $48.3M | $42.3M | $43.4M | $49.5M | $52.3M | $56.4M | $51.2M | $50.3M |
| Inventory | $10.6M | $10.5M | $10.3M | $8.7M | $8.4M | $6.8M | $8.1M | $6.6M |
| Marketable securities (non-current) | — | — | — | — | — | $5.6M | $0 | — |
| Property, plant & equipment | — | — | — | — | — | — | — | — |
| Goodwill | $10.7M | $10.7M | $10.7M | $10.7M | $10.7M | $10.7M | $10.7M | $10.7M |
| Intangible assets | $84.4M | $86.7M | $88.9M | $91.2M | $93.4M | $67.2M | $95.5M | $99.9M |
| Other non-current assets | $4.4M | $4.3M | $3.8M | $1.3M | $1.2M | $1.3M | $1.2M | $1.8M |
| Accounts payable | $9.7M | $15.0M | $18.7M | $12.2M | $13.2M | $8.5M | $6.9M | $6.8M |
| Deferred revenue (current) | — | — | — | — | — | — | — | — |
| Short-term debt | $2.9M | $1.7M | $417.0K | $0 | $1.9M | $1.1M | $278.0K | $0 |
| Long-term debt | $7.2M | $8.4M | $9.6M | $10.0M | $8.1M | $8.9M | $9.7M | $10.0M |
| Other non-current liabilities | — | — | — | — | — | — | — | — |
| Retained earnings | -$240.9M | -$238.8M | -$224.3M | -$222.0M | -$221.5M | -$226.0M | -$200.1M | -$209.7M |
| Accumulated other comprehensive income (loss) | -$256.0K | -$63.0K | $267.0K | $240.0K | $39.0K | $131.0K | $230.0K | $473.0K |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $15.2M | -$22.1M | $26.9M | $22.6M | $20.8M | -$6.0M | $24.4M | $23.3M |
| Investing cash flow | -$16.0M | -$25.8M | $8.8M | -$18.4M | -$28.4M | -$22.4M | $5.8M | -$14.8M |
| Financing cash flow | -$886.0K | -$5.0M | -$4.6M | -$919.0K | $101.0K | -$1.6M | -$5.4M | $838.0K |
| Free cash flow | $6.6M | -$34.6M | $19.7M | $7.8M | $11.6M | -$10.8M | $16.8M | $17.0M |
| Capital expenditures | $8.7M | $12.5M | $7.2M | $14.8M | $9.3M | $4.7M | $7.6M | $6.4M |
| Depreciation & amortization | $4.1M | $3.9M | $3.8M | $3.8M | $3.4M | $29.8M | $5.8M | $3.5M |
| Share-based compensation | $11.6M | $9.8M | $11.4M | $12.1M | $11.2M | $11.2M | $11.4M | $13.0M |
| Deferred income taxes | -$3.0K | -$10.0K | -$907.0K | $116.0K | -$4.7M | -$770.0K | -$2.3M | $5.2M |
| Change in accounts receivable | $5.8M | -$1.1M | -$6.3M | -$1.9M | -$3.9M | $5.2M | $769.0K | $4.3M |
| Change in inventory | $119.0K | $207.0K | $1.6M | $307.0K | $1.5M | -$1.3M | $1.6M | -$1.4M |
| Change in accounts payable | -$2.3M | $3.2M | -$17.0K | $1.4M | $1.1M | $615.0K | -$570.0K | -$2.2M |
| Purchases of investments | $54.5M | $55.1M | $37.4M | $58.5M | $44.4M | $48.4M | $47.3M | $45.2M |
| Tax withholding on stock comp | $793.0K | $6.6M | $7.4M | $1.2M | $589.0K | $2.5M | $6.4M | $1.3M |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Revenue | $344.2M | $332.1M | $219.8M | $137.0M | $94.1M |
| Gross profit | — | — | — | — | — |
| Operating income | -$42.8M | $8.7M | -$68.0M | -$72.9M | -$40.1M |
| Net income | -$24.2M | $18.2M | -$57.5M | -$67.1M | -$31.3M |
| EPS (diluted) | $-0.83 | $0.62 | $-2.14 | $-2.58 | $-1.24 |
| EPS (basic) | $-0.83 | $0.66 | $-2.14 | $-2.58 | $-1.24 |
| Operating margin | -$12 | $3 | -$31 | -$53 | -$43 |
| Net margin | -$7 | $5 | -$26 | -$49 | -$33 |
Balance sheet
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Total assets | $578.6M | $531.2M | $453.3M | $447.3M | $462.6M |
| Total liabilities | $107.7M | $75.4M | $62.1M | $48.2M | $50.8M |
| Stockholders' equity | $470.9M | $455.8M | $391.3M | $399.1M | $411.7M |
| Total current assets | $361.1M | $360.2M | $295.6M | $292.3M | $353.7M |
| Total current liabilities | $68.7M | $49.4M | $47.7M | $36.1M | $24.9M |
| Cash & equivalents | $116.7M | $119.7M | $98.8M | $122.9M | $329.6M |
| Marketable securities (current) | $182.8M | $173.4M | $144.3M | — | — |
| Accounts receivable | $43.4M | $51.2M | $38.3M | $23.5M | $17.3M |
| Inventory | $10.3M | $8.1M | $7.9M | $4.0M | $2.0M |
| Property, plant & equipment | — | — | — | $14.3M | $9.5M |
| Goodwill | $10.7M | $10.7M | $10.7M | $10.7M | $0 |
| Intangible assets | $88.9M | $95.5M | $106.6M | $115.7M | $88.9M |
| Other non-current assets | $3.8M | $1.2M | $1.4M | $1.1M | $1.7M |
| Accounts payable | $18.7M | $6.9M | $10.3M | $4.7M | $2.5M |
| Deferred revenue (current) | — | — | — | — | $0 |
| Short-term debt | $417.0K | $278.0K | $0 | — | — |
| Long-term debt | $9.6M | $9.7M | $0 | — | — |
| Other non-current liabilities | — | — | $25.0K | $90.0K | $124.0K |
| Retained earnings | -$224.3M | -$200.1M | -$218.4M | -$160.9M | -$93.8M |
| Accumulated other comprehensive income (loss) | $267.0K | $230.0K | $136.0K | -$381.0K | $0 |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating cash flow | $64.3M | $64.9M | -$5.6M | -$41.7M | -$19.0M |
| Investing cash flow | -$60.4M | -$50.1M | -$16.2M | -$166.5M | -$66.7M |
| Financing cash flow | -$7.0M | $6.1M | -$2.3M | $1.5M | $5.4M |
| Free cash flow | $28.3M | $36.5M | -$19.2M | -$47.3M | -$22.5M |
| Capital expenditures | $36.0M | $28.3M | $13.6M | $5.6M | $3.5M |
| Depreciation & amortization | $40.8M | $16.0M | $12.3M | $10.5M | $3.4M |
| Share-based compensation | $45.9M | $50.3M | $51.2M | $36.3M | $21.7M |
| Deferred income taxes | -$6.2M | $1.4M | -$223.0K | -$1.9M | -$8.7M |
| Change in accounts receivable | -$6.9M | $12.6M | $14.9M | $6.2M | $4.6M |
| Change in inventory | $2.1M | $193.0K | $4.0M | $1.7M | -$327.0K |
| Change in accounts payable | $3.1M | -$4.4M | $5.7M | $582.0K | -$182.0K |
| Purchases of investments | $188.7M | $205.7M | $189.1M | $134.7M | $0 |
| Tax withholding on stock comp | $11.7M | $8.8M | $5.1M | $1.7M | $781.0K |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding CSTL as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Institutional ownership is not available for this symbol right now.
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2025-11-24 to 2026-10-19
Recent transactions
- Insiders have net sold 298,306 shares over the last 182 days, across 0 purchases and 104 sales.
- Most recent: MAETZOLD DEREK J (Pres. & Chief Exec. Officer) — Open market sale of 8,580 shares on 2026-10-19.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Purchases (open market)0 sh(0 txns)
Sales (open market)298,306 sh(104 txns)
Net Shares-298,306
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| MAETZOLD DEREK J | Pres. & Chief Exec. Officer | Open market sale | 2026-10-19 | 8,580 |
| Juvenal Tobin W | Chief Commercial Officer | Open market sale | 2026-10-12 | 3,288 |
| Oelschlager Kristen M | Chief Operating Officer | Option exercise | 2026-10-01 | 4,153 |
| Stokes Frank | Chief Financial Officer | Open market sale | 2026-08-14 | 24,908 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2026-10-19 | MAETZOLD DEREK J | Pres. & Chief Exec. Officer | Open market sale | 8,580 | $31.91 |
| 2026-10-19 | MAETZOLD DEREK J | Pres. & Chief Exec. Officer | Open market sale | 3,198 | $31.91 |
| 2026-10-19 | MAETZOLD DEREK J | Pres. & Chief Exec. Officer | Open market sale | 2,718 | $31.91 |
| 2026-10-12 | Juvenal Tobin W | Chief Commercial Officer | Open market sale | 3,288 | $33.64 |
| 2026-10-05 | MAETZOLD DEREK J | Pres. & Chief Exec. Officer | Option exercise | 8,165 | $2.39 |
| 2026-10-05 | MAETZOLD DEREK J | Pres. & Chief Exec. Officer | Open market sale | 8,580 | $35.57 |
| 2026-10-05 | MAETZOLD DEREK J | Pres. & Chief Exec. Officer | Open market sale | 3,198 | $35.57 |
| 2026-10-05 | MAETZOLD DEREK J | Pres. & Chief Exec. Officer | Open market sale | 2,718 | $35.57 |
| 2026-10-01 | Oelschlager Kristen M | Chief Operating Officer | Option exercise | 4,153 | $3.38 |
| 2026-10-01 | Oelschlager Kristen M | Chief Operating Officer | Open market sale | 2,807 | $35.75 |
| 2026-10-01 | Oelschlager Kristen M | Chief Operating Officer | Open market sale | 1,346 | $36.38 |
| 2026-09-30 | Juvenal Tobin W | Chief Commercial Officer | Open market sale | 1,034 | $34.20 |
| 2026-09-29 | Juvenal Tobin W | Chief Commercial Officer | Open market sale | 5,543 | $35.50 |
| 2026-09-21 | MAETZOLD DEREK J | Pres. & Chief Exec. Officer | Option exercise | 8,580 | $2.39 |
| 2026-09-21 | MAETZOLD DEREK J | Pres. & Chief Exec. Officer | Open market sale | 8,580 | $35.33 |
| 2026-09-21 | MAETZOLD DEREK J | Pres. & Chief Exec. Officer | Open market sale | 3,198 | $35.33 |
| 2026-09-21 | MAETZOLD DEREK J | Pres. & Chief Exec. Officer | Open market sale | 2,718 | $35.33 |
| 2026-09-15 | Juvenal Tobin W | Chief Commercial Officer | Open market sale | 3,294 | $35.14 |
| 2026-09-14 | Juvenal Tobin W | Chief Commercial Officer | Open market sale | 3,306 | $32.32 |
| 2026-09-11 | MAETZOLD DEREK J | Pres. & Chief Exec. Officer | Option exercise | 8,584 | $2.39 |
| 2026-09-11 | MAETZOLD DEREK J | Pres. & Chief Exec. Officer | Open market sale | 8,361 | $32.00 |
| 2026-09-11 | MAETZOLD DEREK J | Pres. & Chief Exec. Officer | Open market sale | 3,124 | $32.00 |
| 2026-09-11 | MAETZOLD DEREK J | Pres. & Chief Exec. Officer | Open market sale | 2,656 | $32.00 |
| 2026-09-11 | MAETZOLD DEREK J | Pres. & Chief Exec. Officer | Open market sale | 223 | $32.78 |
| 2026-09-11 | MAETZOLD DEREK J | Pres. & Chief Exec. Officer | Open market sale | 83 | $32.78 |
| 2026-09-11 | MAETZOLD DEREK J | Pres. & Chief Exec. Officer | Open market sale | 71 | $32.78 |
| 2026-09-01 | Oelschlager Kristen M | Chief Operating Officer | Option exercise | 4,152 | $3.38 |
| 2026-09-01 | Oelschlager Kristen M | Chief Operating Officer | Open market sale | 3,952 | $33.36 |
| 2026-09-01 | Oelschlager Kristen M | Chief Operating Officer | Open market sale | 200 | $34.02 |
| 2026-08-31 | Juvenal Tobin W | Chief Commercial Officer | Open market sale | 1,730 | $32.81 |
| 2026-08-28 | MAETZOLD DEREK J | Pres. & Chief Exec. Officer | Option exercise | 12,428 | $2.39 |
| 2026-08-28 | MAETZOLD DEREK J | Pres. & Chief Exec. Officer | Open market sale | 11,472 | $33.14 |
| 2026-08-28 | MAETZOLD DEREK J | Pres. & Chief Exec. Officer | Open market sale | 2,505 | $33.14 |
| 2026-08-28 | MAETZOLD DEREK J | Pres. & Chief Exec. Officer | Open market sale | 2,129 | $33.14 |
| 2026-08-28 | MAETZOLD DEREK J | Pres. & Chief Exec. Officer | Open market sale | 257 | $33.14 |
| 2026-08-28 | MAETZOLD DEREK J | Pres. & Chief Exec. Officer | Open market sale | 257 | $33.14 |
| 2026-08-28 | MAETZOLD DEREK J | Pres. & Chief Exec. Officer | Open market sale | 257 | $33.14 |
| 2026-08-28 | MAETZOLD DEREK J | Pres. & Chief Exec. Officer | Open market sale | 257 | $33.14 |
| 2026-08-28 | MAETZOLD DEREK J | Pres. & Chief Exec. Officer | Open market sale | 956 | $33.88 |
| 2026-08-28 | MAETZOLD DEREK J | Pres. & Chief Exec. Officer | Open market sale | 209 | $33.88 |
| 2026-08-28 | MAETZOLD DEREK J | Pres. & Chief Exec. Officer | Open market sale | 177 | $33.88 |
| 2026-08-28 | MAETZOLD DEREK J | Pres. & Chief Exec. Officer | Open market sale | 21 | $33.88 |
| 2026-08-28 | MAETZOLD DEREK J | Pres. & Chief Exec. Officer | Open market sale | 21 | $33.88 |
| 2026-08-28 | MAETZOLD DEREK J | Pres. & Chief Exec. Officer | Open market sale | 21 | $33.88 |
| 2026-08-28 | MAETZOLD DEREK J | Pres. & Chief Exec. Officer | Open market sale | 21 | $33.88 |
| 2026-08-25 | Juvenal Tobin W | Chief Commercial Officer | Open market sale | 9,050 | $35.04 |
| 2026-08-25 | Oelschlager Kristen M | Chief Operating Officer | Open market sale | 7,161 | $34.26 |
| 2026-08-25 | Oelschlager Kristen M | Chief Operating Officer | Open market sale | 5,223 | $34.64 |
| 2026-08-24 | Oelschlager Kristen M | Chief Operating Officer | Open market sale | 12,218 | $33.69 |
| 2026-08-17 | Juvenal Tobin W | Chief Commercial Officer | Open market sale | 1,730 | $29.59 |
| 2026-08-14 | Stokes Frank | Chief Financial Officer | Open market sale | 24,908 | $29.77 |
| 2026-08-14 | MAETZOLD DEREK J | Pres. & Chief Exec. Officer | Option exercise | 1,100 | $2.39 |
| 2026-08-14 | MAETZOLD DEREK J | Pres. & Chief Exec. Officer | Open market sale | 1,100 | $30.02 |
| 2026-08-14 | MAETZOLD DEREK J | Pres. & Chief Exec. Officer | Open market sale | 2,714 | $30.02 |
| 2026-08-14 | MAETZOLD DEREK J | Pres. & Chief Exec. Officer | Open market sale | 2,306 | $30.02 |
| 2026-08-14 | MAETZOLD DEREK J | Pres. & Chief Exec. Officer | Open market sale | 278 | $30.02 |
| 2026-08-14 | MAETZOLD DEREK J | Pres. & Chief Exec. Officer | Open market sale | 278 | $30.02 |
| 2026-08-14 | MAETZOLD DEREK J | Pres. & Chief Exec. Officer | Open market sale | 278 | $30.02 |
| 2026-08-14 | MAETZOLD DEREK J | Pres. & Chief Exec. Officer | Open market sale | 278 | $30.02 |
| 2026-08-05 | MAETZOLD DEREK J | Pres. & Chief Exec. Officer | Option exercise | 2,546 | $2.39 |
Showing the most recent 60 transactions.
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-22 08:23 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-10-21 | 4 | 2026-10-19 | View on SEC.gov → |
| 2026-10-14 | 4 | 2026-10-12 | View on SEC.gov → |
| 2026-10-07 | 4 | 2026-10-05 | View on SEC.gov → |
| 2026-10-05 | 4 | 2026-10-01 | View on SEC.gov → |
| 2026-10-01 | 4 | 2026-09-29 | View on SEC.gov → |
| 2026-09-23 | 4 | 2026-09-21 | View on SEC.gov → |
| 2026-09-16 | 4 | 2026-09-14 | View on SEC.gov → |
| 2026-09-15 | 4 | 2026-09-11 | View on SEC.gov → |
| 2026-09-03 | 4 | 2026-09-01 | View on SEC.gov → |
| 2026-09-02 | 4 | 2026-08-31 | View on SEC.gov → |
| 2026-09-01 | 4 | 2026-08-28 | View on SEC.gov → |
| 2026-08-27 | 4 | 2026-08-25 | View on SEC.gov → |
Recent news
Headlines about CSTL (Castle Biosciences, Inc.). Links open the publisher — we don’t host full articles.
-
Castle Biosciences CEO Derek Maetzold sells $462,567 in stock
Investing.com · 2026-10-22 -
Insider Selling: Castle Biosciences (NASDAQ:CSTL) Insider Sells 8,580 Shares of Company Stock
MarketBeat · 2026-10-21 -
Form 4 Castle Biosciences Inc: Derek J. Maetzold (Director, Pres. & Chief Exec. Officer) For: 19 October
Investing.com UK · 2026-10-21 -
(CSTL) Price Dynamics and Execution-Aware Positioning
Stock Traders Daily · 2026-10-21 -
CSTL270416C00045000 Interactive Stock Chart | CSTL Apr 2027 45.000 call Stock
Yahoo Finance · 2026-10-21 -
Castle Biosciences Q3 2026 Earnings Date and Estimates
MarketBeat · 2026-10-18 -
CSTL261016P00030000 Interactive Stock Chart | CSTL Oct 2026 30.000 put Stock
Yahoo Finance · 2026-10-16 -
Castle Biosciences to Release Third Quarter 2026 Financial Results and Host Webcast on Thursday, Nov. 5, 2026
Yahoo · 2026-10-15
No headlines in this category right now — try “All”.